J Mult Scler Neuroimmunol.
2024 Dec;15(2):43-48. 10.59578/jmsni.2024.15.2.43-48.
Eculizumab Therapy in Neuromyelitis Optica Spectrum Disorder
- Affiliations
-
- 1Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea
- 2Department of Neurology, Chung Ang University College of Medicine, Seoul, Korea
- KMID: 2563830
- DOI: http://doi.org/10.59578/jmsni.2024.15.2.43-48
Abstract
- Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease that causes recurrent inflammation in the central nervous system which has poor prognosis without appropriate treatment. Complement activation mediated by aquaporin-4 antibodies play a main role in pathogenicity of NMOSD. Recently, four novel drugs targeting specific pathomechanism of NMOSD, eculizumab, satralizumab, inebilizumab, and ravulizumab, were introduced in worldwide and the results of randomized controlled trial of these rising stars were encouraging. Eculizamb, inhibitor of the complement system (C5 protein), was approved for their use in seropositive NMOSD in Republic of Korea since April 2024. Here, we introduce the mechanism of action of eculizumab, and its clinical data to evaluate its therapeutic value.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Monoclonal Antibody Therapies for Neuromyelitis Optica Spectrum Disorder
- Postpartum Relapse of Neuromyelitis Optica Spectrum Disorder after a Long Period of Spontaneous Remission
- Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder
- Early relapse after rituximab treatment in a patient with seronegative neuromyelitis optica spectrum disorder: a case report
- Monoclonal Antibody Treatment for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder
